Compounds > 1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene
Page last updated: 2024-09-03

1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene and Epithelial Ovarian Cancer

1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene has been researched along with Epithelial Ovarian Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Czajkowski, M; Józkowiak, M; Nowicki, A; Pawlak, M; Piotrowska-Kempisty, H; Rolle, K; Skupin-Mrugalska, P; Wawrzyniak, D; Wierzchowski, M1

Other Studies

1 other study(ies) available for 1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene and Epithelial Ovarian Cancer

ArticleYear
Enhanced biological activity of liposomal methylated resveratrol analog 3'-hydroxy-3,4,5,4'-tetramethoxystilbene (DMU-214) in 3D patient-derived ovarian cancer model.
    Drug delivery, 2022, Volume: 29, Issue:1

    Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; Liposomes; Ovarian Neoplasms; Resveratrol; Stilbenes

2022